Phoenix Financial Ltd. Raises Stock Position in Edwards Lifesciences Corporation $EW

Phoenix Financial Ltd. raised its stake in Edwards Lifesciences Corporation (NYSE:EW) by 167.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,390 shares of the medical research company’s stock after buying an additional 6,502 shares during the period. Phoenix Financial Ltd.’s holdings in Edwards Lifesciences were worth $886,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Brighton Jones LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $266,000. NewEdge Advisors LLC grew its position in shares of Edwards Lifesciences by 8.1% in the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after purchasing an additional 2,665 shares during the last quarter. Sei Investments Co. grew its position in shares of Edwards Lifesciences by 16.7% in the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after purchasing an additional 58,988 shares during the last quarter. Squarepoint Ops LLC grew its position in shares of Edwards Lifesciences by 277.7% in the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after purchasing an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina grew its position in shares of Edwards Lifesciences by 0.4% in the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after purchasing an additional 1,065 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction on Friday, May 1st. The shares were sold at an average price of $83.01, for a total value of $84,587.19. Following the transaction, the vice president owned 33,934 shares in the company, valued at $2,816,861.34. This trade represents a 2.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the completion of the transaction, the vice president owned 21,266 shares in the company, valued at approximately $1,782,941.44. This trade represents a 53.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 88,096 shares of company stock worth $7,288,799 in the last quarter. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Stock Up 0.0%

Shares of NYSE EW opened at $81.34 on Friday. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $87.89. The firm’s 50 day moving average price is $81.50 and its 200 day moving average price is $82.86. The firm has a market cap of $46.84 billion, a P/E ratio of 43.27, a price-to-earnings-growth ratio of 2.04 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same quarter last year, the business earned $0.64 earnings per share. Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analysts Set New Price Targets

EW has been the topic of several research reports. Robert W. Baird increased their price target on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Mizuho set a $95.00 price target on shares of Edwards Lifesciences and gave the company an “outperform” rating in a research report on Monday, April 13th. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Evercore restated an “outperform” rating and set a $93.00 target price on shares of Edwards Lifesciences in a research report on Friday, April 24th. Finally, Truist Financial set a $90.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $95.65.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.